Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy

By Giaccone Giuseppe   Iacona Renee   Fandi Abderrahim   Janas Mette   Ochs Judith   Herbst Roy   Johnson David  

Journal of Cancer Research and Clinical Oncology, Vol. 135, Iss. 3, 2009-03 ,pp. : 467-476

Springer Publishing Company

Access to resources Recommend Favorite

Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis

By Wei Shu-zhen  

Medical Oncology, Vol. 28, Iss. 1, 2011-03 ,pp. : 315-321

Humana Press, Inc

Access to resources Recommend Favorite

Second-line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: A phase II trial

By Tas Faruk   Demir Cumhur   Camlica Hakan   Ustuner Zeki   Topuz Erkan  

Medical Oncology, Vol. 21, Iss. 3, 2004-09 ,pp. : 233-240

Humana Press, Inc

Access to resources Recommend Favorite

Prognostic implications of survivin and lung resistance protein in advanced non-small cell lung cancer treated with platinum-based chemotherapy

By                      

Oncology Letters, Vol. 11, Iss. 1, 2016-01 ,pp. : 723-730

Spandidos Publications

Access to resources Recommend Favorite

Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy

By Wilop Stefan   Hobe Sabine   Crysandt Martina   Esser Albert   Osieka Rainhardt   Jost Edgar  

Journal of Cancer Research and Clinical Oncology, Vol. 135, Iss. 10, 2009-10 ,pp. : 1429-1435

Springer Publishing Company

Access to resources Recommend Favorite